Ahmed M. Malki
Department of Health Sciences
Qatar University, Qatar
Dr Ahmed M Malki received his PhD in Biochemistry in 2006 in the field of Molecular Oncology from Edison Institute of Biotechnology, Chemistry and Biochemistry Department, Ohio University in USA. Dr Malki awarded best publication from Chemistry and Biochemistry Department, Ohio University in 2005. Dr Maki held postdoctoral position at University of California Berkeley, USA via NIH grant in 2007. Dr Malki appointed as Head of Molecular therapeutics laboratories at City of Research and Technology in 200. Dr Malki also received Best Research Award, Global Breast Cancer conference, 2011, Seoul, South Korea and Alexandria University Award for Scientific encouragement in 2012. Dr Malki awarded international and national grants for discovery of novel small molecules targeting cancer cells; he has many peer reviewed international publications and He is serving in editorial board member in number of international journals. Dr Malki presented his research as invited speaker at international conferences and professional meetings. The central theme of Dr Malki's research is the understanding of the signaling pathways that regulate cell proliferation, cell death and designing novel anticancer drugs targeting p53.
The central theme of my research is the understanding of the signaling pathways that regulate cell proliferation and cell death and designing novel anticancer drugs. Signaling transduction pathways and networks have recently proven to be attractive targets for cancer therapy. Aberrancies of cell growth and cell death are fundamental problems that contribute to the pathogenesis of virtually all forms of cancer. The development and utilization of novel molecular therapeutics requires a detailed understanding of the signaling aberrations present in tumors. Additionally, many forms of cancer therapeutics have the intent of inhibiting cell proliferation or inducing cell death. Most cytotoxic agents used to treat cancer act by inducing apoptosis However, a critical flaw in developing and utilizing anticancer drugs is that most also harm normal cells. Hence, it is important to identify compounds that are more potent to cancer cells than to the normal counterparts.